Alma Bio Therapeutics
  • Home
  • About Us
    • About Us
    • The People
  • Our Approach
    • Autoimmune Diseases
    • Our Therapeutic Approach
  • Pipeline
  • News
  • Contact Us

Author: Dan Gelvan

This author has written 5 articles

Alma Bio Therapeutics will present at the French-Israeli joint healthcare event in Paris

  • Dan Gelvan
  • November 17, 2019
  • News Archive
  • 0 Comments

December 2019 - Alma Bio Therapeutics will be attending the French-Israeli joint event in the healthcare sector, Paris December 10, 2019, sponsored by the BPI, the French Public Investment Bank. As part…

Continue Reading

Alma will present at the EIT Health Summit 2019

  • Dan Gelvan
  • November 17, 2019
  • News Archive
  • 0 Comments

December 2019  - Alma has been invited to present at the EIT Health Summit 2019, December 2-3 Paris. Come and meet us there.

Continue Reading

Alma receives the EMA’s scientific advice for its lead product

  • Dan Gelvan
  • November 17, 2019
  • News Archive
  • 0 Comments

October 2019 -  Alma receives the EMA's CHMP (Committee for Medicinal Products for Human Use) scientific advice. The Agency's advice concerned quality development, pre-clinical development and clinical development for the…

Continue Reading

Alma is featured in Cello Health BioConsulting’s panel on autoimmune diseases

  • Dan Gelvan
  • November 17, 2019
  • News Archive
  • 0 Comments

August 2019 - Alma is featured in Cello Health BioConsulting's "Next-generation-therapies-for-autoimmune-and-inflammatory-diseases". Alma is listed among the "next generation approaches in development with novel targets and modalities"

Continue Reading

Alain P. Rolland joins Alma’s scientific advisory board

  • Dan Gelvan
  • November 17, 2019
  • News Archive
  • 0 Comments

January 2019 - Alma appointed Dr. Alain P. Rolland to serve on its scientific advisory board. Dr. Rolland's appointment will strengthen Alma's capacities in the fields of DNA drugs and…

Continue Reading

Recent Posts

  • Drug Mechanism of Action demonstrated: Mucosal healing without immune suppression
  • New PCT: Nucleic acid therapy for differential modulation of host microflora
  • ECCO 2022
  • CCFI /Région Auvergne Rhône-Alpes
  • 4th Antigen Specific Immune Tolerance event

Questions? Contact Us!

Site Navigation

  • Home
  • About Us
  • Our Approach
  • Pipeline
  • News
  • Legal Notice

Contact Info

  • ALMA BIO THERAPEUTICS
  • HQ Lyon Vaise Business Center
    3, place Giovanni Da Verrazzano
    Lyon 69009 France
  • +33 4 37 66 47 49
  • message@alma-bio.com
© All Right Reserved to Alma Bio Therapeutics 2018